But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt. So, the natural question for Metsera (NASDAQ:MTSR) shareholders is whether they should be ...

VESPER-1 and interim VESPER-3 data release expected in September 2025; Phase 3 initiation on track for late 2025 MET-233i (once-monthly amylin analog) delivered class-leading Phase 1 results including ...

VESPER-1 and interim VESPER-3 data release expected in September 2025; Phase 3 initiation on track for late 2025 MET-233i (once-monthly amylin analog) delivered ...

Investing.com -- Metsera , Inc. (NASDAQ: MTSR ), a clinical-stage biopharmaceutical company focused on obesity and metabolic diseases, reported a wider-than-expected second quarter loss on Monday, ...

Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and ...

Metsera, Inc. (NASDAQ:MTSR) is a clinical-stage biopharmaceutical company that focuses on new medicines for obesity and metabolic diseases. While we acknowledge the potential of MTSR as an investment, ...

When InvestingPro’s Fair Value models identified Metsera Inc. (NASDAQ:MTSR) as significantly undervalued on April 1, 2025, the healthcare company’s stock was trading at $24.51. Just three and ...

When InvestingPro’s Fair Value models identified Metsera Inc. (NASDAQ:MTSR) as significantly undervalued on April 1, 2025, the healthcare company’s stock was trading at $24.51. Just three and a half ...

Metsera, a healthcare company focused on developing innovative treatments for obesity and metabolic disorders, had been flying under the radar despite its promising pipeline. When InvestingPro’s ...

Gain insights into Amneal Pharmaceuticals' Q2 2025 success, with strong growth, upgraded guidance, and promising launches like CREXONT and Brekiya.

Metsera, Inc. (NASDAQ:MTSR) is one of the 11 Hot New Stocks to Invest in Now. On June 22, Metsera, Inc. (NASDAQ:MTSR) presented at the 85th Scientific Sessions of the American Diabetes Association.